Selected research
Market Structure
Global Human Hepatitis B Immunoglobulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Human Hepatitis B Immunoglobulin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Human Hepatitis B Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Human Hepatitis B Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Human Hepatitis B Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Human Hepatitis B Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Human Hepatitis B Immunoglobulin include Shanghai Institute of Biological, China Biologic, Sichuan Yuanda Shuyang, Shanghai RAAS, Shuanglin Bio-pharmacy, Boya Bio-pharmaceutical, Hualan Biological, Tiantan Biologic and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Human Hepatitis B Immunoglobulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Human Hepatitis B Immunoglobulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Human Hepatitis B Immunoglobulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Hepatitis B Immunoglobulin market size, projected growth trends, production technologies, key applications, and end-use industries.
Human Hepatitis B Immunoglobulin Segment by Company
Shanghai Institute of Biological
China Biologic
Sichuan Yuanda Shuyang
Shanghai RAAS
Shuanglin Bio-pharmacy
Boya Bio-pharmaceutical
Hualan Biological
Tiantan Biologic
Bayer
Baxter
Octapharma
Grifols
CSL
Human Hepatitis B Immunoglobulin Segment by Type
400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
Human Hepatitis B Immunoglobulin Segment by Application
Hepatitis B Carrier
Hepatitis B Close Contacts
Human Hepatitis B Immunoglobulin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Hepatitis B Immunoglobulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Hepatitis B Immunoglobulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Hepatitis B Immunoglobulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Human Hepatitis B Immunoglobulin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Hepatitis B Immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Hepatitis B Immunoglobulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Human Hepatitis B Immunoglobulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
Applications
- Hepatitis B Carrier
- Hepatitis B Close Contacts
Companies covered
- Shanghai Institute of Biological
- China Biologic
- Sichuan Yuanda Shuyang
- Shanghai RAAS
- Shuanglin Bio-pharmacy
- Boya Bio-pharmaceutical
- Hualan Biological
- Tiantan Biologic
- Bayer
- Baxter
- Octapharma
- Grifols
- CSL
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Human Hepatitis B Immunoglobulin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Human Hepatitis B Immunoglobulin Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Human Hepatitis B Immunoglobulin Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Human Hepatitis B Immunoglobulin Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Human Hepatitis B Immunoglobulin Market Dynamics
- 2.1 Human Hepatitis B Immunoglobulin Industry Trends
- 2.2 Human Hepatitis B Immunoglobulin Industry Drivers
- 2.3 Human Hepatitis B Immunoglobulin Industry Opportunities and Challenges
- 2.4 Human Hepatitis B Immunoglobulin Industry Restraints
3 Human Hepatitis B Immunoglobulin Market by Manufacturers
- 3.1 Global Human Hepatitis B Immunoglobulin Revenue by Manufacturers (2021-2026)
- 3.2 Global Human Hepatitis B Immunoglobulin Sales by Manufacturers (2021-2026)
- 3.3 Global Human Hepatitis B Immunoglobulin Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Human Hepatitis B Immunoglobulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Human Hepatitis B Immunoglobulin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Human Hepatitis B Immunoglobulin Manufacturers, Product Type & Application
- 3.7 Global Human Hepatitis B Immunoglobulin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Human Hepatitis B Immunoglobulin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Human Hepatitis B Immunoglobulin Players Market Share by Revenue in 2025
- 3.8.3 2025 Human Hepatitis B Immunoglobulin Tier 1, Tier 2, and Tier 3
4 Human Hepatitis B Immunoglobulin Market by Type
- 4.1 Human Hepatitis B Immunoglobulin Type Introduction
- 4.1.1 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- 4.1.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- 4.1.3 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- 4.2 Global Human Hepatitis B Immunoglobulin Sales by Type
- 4.2.1 Global Human Hepatitis B Immunoglobulin Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Human Hepatitis B Immunoglobulin Sales by Type (2021-2032)
- 4.2.3 Global Human Hepatitis B Immunoglobulin Sales Market Share by Type (2021-2032)
- 4.3 Global Human Hepatitis B Immunoglobulin Revenue by Type
- 4.3.1 Global Human Hepatitis B Immunoglobulin Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Human Hepatitis B Immunoglobulin Revenue by Type (2021-2032)
- 4.3.3 Global Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2021-2032)
5 Human Hepatitis B Immunoglobulin Market by Application
- 5.1 Human Hepatitis B Immunoglobulin Application Introduction
- 5.1.1 Hepatitis B Carrier
- 5.1.2 Hepatitis B Close Contacts
- 5.2 Global Human Hepatitis B Immunoglobulin Sales by Application
- 5.2.1 Global Human Hepatitis B Immunoglobulin Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Human Hepatitis B Immunoglobulin Sales by Application (2021-2032)
- 5.2.3 Global Human Hepatitis B Immunoglobulin Sales Market Share by Application (2021-2032)
- 5.3 Global Human Hepatitis B Immunoglobulin Revenue by Application
- 5.3.1 Global Human Hepatitis B Immunoglobulin Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Human Hepatitis B Immunoglobulin Revenue by Application (2021-2032)
- 5.3.3 Global Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2021-2032)
6 Global Human Hepatitis B Immunoglobulin Sales by Region
- 6.1 Global Human Hepatitis B Immunoglobulin Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Human Hepatitis B Immunoglobulin Sales by Region (2021-2032)
- 6.2.1 Global Human Hepatitis B Immunoglobulin Sales by Region (2021-2026)
- 6.2.2 Global Human Hepatitis B Immunoglobulin Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Human Hepatitis B Immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Human Hepatitis B Immunoglobulin Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Human Hepatitis B Immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Human Hepatitis B Immunoglobulin Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Human Hepatitis B Immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Human Hepatitis B Immunoglobulin Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Human Hepatitis B Immunoglobulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Human Hepatitis B Immunoglobulin Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Human Hepatitis B Immunoglobulin Revenue by Region
- 7.1 Global Human Hepatitis B Immunoglobulin Revenue by Region
- 7.1.1 Global Human Hepatitis B Immunoglobulin Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Human Hepatitis B Immunoglobulin Revenue by Region (2021-2026)
- 7.1.3 Global Human Hepatitis B Immunoglobulin Revenue by Region (2027-2032)
- 7.1.4 Global Human Hepatitis B Immunoglobulin Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Human Hepatitis B Immunoglobulin Revenue (2021-2032)
- 7.2.2 North America Human Hepatitis B Immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Human Hepatitis B Immunoglobulin Revenue (2021-2032)
- 7.3.2 Europe Human Hepatitis B Immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Human Hepatitis B Immunoglobulin Revenue (2021-2032)
- 7.4.2 Asia-Pacific Human Hepatitis B Immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Human Hepatitis B Immunoglobulin Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Human Hepatitis B Immunoglobulin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Shanghai Institute of Biological
- 8.1.1 Shanghai Institute of Biological Company Information
- 8.1.2 Shanghai Institute of Biological Business Overview
- 8.1.3 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Product Portfolio
- 8.1.5 Shanghai Institute of Biological Recent Developments
- 8.2 China Biologic
- 8.2.1 China Biologic Company Information
- 8.2.2 China Biologic Business Overview
- 8.2.3 China Biologic Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 China Biologic Human Hepatitis B Immunoglobulin Product Portfolio
- 8.2.5 China Biologic Recent Developments
- 8.3 Sichuan Yuanda Shuyang
- 8.3.1 Sichuan Yuanda Shuyang Company Information
- 8.3.2 Sichuan Yuanda Shuyang Business Overview
- 8.3.3 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Product Portfolio
- 8.3.5 Sichuan Yuanda Shuyang Recent Developments
- 8.4 Shanghai RAAS
- 8.4.1 Shanghai RAAS Company Information
- 8.4.2 Shanghai RAAS Business Overview
- 8.4.3 Shanghai RAAS Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Shanghai RAAS Human Hepatitis B Immunoglobulin Product Portfolio
- 8.4.5 Shanghai RAAS Recent Developments
- 8.5 Shuanglin Bio-pharmacy
- 8.5.1 Shuanglin Bio-pharmacy Company Information
- 8.5.2 Shuanglin Bio-pharmacy Business Overview
- 8.5.3 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Product Portfolio
- 8.5.5 Shuanglin Bio-pharmacy Recent Developments
- 8.6 Boya Bio-pharmaceutical
- 8.6.1 Boya Bio-pharmaceutical Company Information
- 8.6.2 Boya Bio-pharmaceutical Business Overview
- 8.6.3 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Product Portfolio
- 8.6.5 Boya Bio-pharmaceutical Recent Developments
- 8.7 Hualan Biological
- 8.7.1 Hualan Biological Company Information
- 8.7.2 Hualan Biological Business Overview
- 8.7.3 Hualan Biological Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Hualan Biological Human Hepatitis B Immunoglobulin Product Portfolio
- 8.7.5 Hualan Biological Recent Developments
- 8.8 Tiantan Biologic
- 8.8.1 Tiantan Biologic Company Information
- 8.8.2 Tiantan Biologic Business Overview
- 8.8.3 Tiantan Biologic Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Tiantan Biologic Human Hepatitis B Immunoglobulin Product Portfolio
- 8.8.5 Tiantan Biologic Recent Developments
- 8.9 Bayer
- 8.9.1 Bayer Company Information
- 8.9.2 Bayer Business Overview
- 8.9.3 Bayer Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Bayer Human Hepatitis B Immunoglobulin Product Portfolio
- 8.9.5 Bayer Recent Developments
- 8.10 Baxter
- 8.10.1 Baxter Company Information
- 8.10.2 Baxter Business Overview
- 8.10.3 Baxter Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Baxter Human Hepatitis B Immunoglobulin Product Portfolio
- 8.10.5 Baxter Recent Developments
- 8.11 Octapharma
- 8.11.1 Octapharma Company Information
- 8.11.2 Octapharma Business Overview
- 8.11.3 Octapharma Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Octapharma Human Hepatitis B Immunoglobulin Product Portfolio
- 8.11.5 Octapharma Recent Developments
- 8.12 Grifols
- 8.12.1 Grifols Company Information
- 8.12.2 Grifols Business Overview
- 8.12.3 Grifols Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Grifols Human Hepatitis B Immunoglobulin Product Portfolio
- 8.12.5 Grifols Recent Developments
- 8.13 CSL
- 8.13.1 CSL Company Information
- 8.13.2 CSL Business Overview
- 8.13.3 CSL Human Hepatitis B Immunoglobulin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 CSL Human Hepatitis B Immunoglobulin Product Portfolio
- 8.13.5 CSL Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Human Hepatitis B Immunoglobulin Value Chain Analysis
- 9.1.1 Human Hepatitis B Immunoglobulin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Human Hepatitis B Immunoglobulin Production Mode & Process
- 9.2 Human Hepatitis B Immunoglobulin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Human Hepatitis B Immunoglobulin Distributors
- 9.2.3 Human Hepatitis B Immunoglobulin Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst